Gene therapy recipients monitored for years in new safety study
NCT ID NCT06885424
First seen May 20, 2026 · Last updated Jun 12, 2026 · Updated 3 times
Summary
This study follows up to 400 people who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The goal is to track long-term side effects and see how well the treatment effects last over time. No new treatment is given—participants simply attend regular check-ups to monitor their health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner Health
Gilbert, Arizona, 85234, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NYU Langone Medical Center
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.